What Is Once-Monthly Oral PrEP? Latest Update 2026
HIV prevention continues to evolve, with one emerging development being a once-monthly oral PrEP option currently in late-stage clinical trials. This investigational medication is designed to reduce the need for daily dosing and may help expand access to HIV prevention in the future.
Although early findings are promising, once-monthly oral PrEP has not yet been approved for use in Thailand. Individuals interested in HIV prevention should stay informed about the latest research while continuing to rely on currently approved and proven prevention methods.
What Is Once-Monthly Oral PrEP?
Once-monthly oral PrEP is an investigational HIV prevention medication designed to be taken only once a month, rather than as a daily regimen. It aims to provide a more convenient option for individuals who want reliable HIV protection but prefer not to take medication every day.
This medication is currently in late-stage clinical trials, meaning it is still being evaluated for safety and effectiveness and is not yet available for clinical use, including in Thailand. Individuals interested in HIV prevention should continue following trusted scientific updates and consult healthcare professionals about the approved PrEP options available today.
Why Develop Once-Monthly Oral PrEP?
One challenge with daily PrEP is maintaining consistent adherence, as many people find it difficult to take a pill every day. A once-monthly oral option is being developed to reduce missed doses and offer greater convenience for individuals who want ongoing HIV protection without the daily routine.
This concept also supports users who prefer a simpler regimen, especially those with irregular schedules or who dislike taking medication frequently. While still under investigation, a once-monthly PrEP option may expand access to HIV prevention for more people in the future.
What Does the Latest 2026 Research Say About Once-Monthly Oral PrEP?
Research updates from 2026 show that once-monthly oral PrEP is now in late-stage clinical trials, where its effectiveness and safety are being evaluated in larger and more diverse participant groups. Earlier-phase studies suggest the drug may maintain adequate protective levels in the body for a full month.
However, ongoing studies must continue to assess safety, potential side effects, and overall performance before it can be considered for approval. These steps are essential to ensure the medication is suitable and reliable for future real-world use.
Is Once-Monthly Oral PrEP Available Yet?
As of 2026, once-monthly oral PrEP has not yet been approved for clinical use, as it remains in late-stage clinical trials. Regulatory review requires comprehensive data on long-term safety, effectiveness, and potential side effects before the medication can be considered for public use.
Although early results are promising, it cannot replace the currently approved PrEP options available today. Individuals seeking HIV prevention should continue using established, approved methods and stay updated through credible medical sources while research progresses.
Comparing Once-Monthly Oral PrEP With Current PrEP Options
Once-monthly oral PrEP aims to reduce dosing frequency, while daily PrEP requires consistent daily intake to maintain its full protective effect. This difference may influence convenience, lifestyle fit, and the likelihood of missed doses for some individuals.
Daily PrEP remains the approved and widely used method in healthcare systems worldwide, including Thailand. In contrast, once-monthly PrEP is still in clinical development and cannot replace existing options. Until new medications receive full approval, individuals should rely on established PrEP regimens for effective HIV prevention.
Who Is Most Suitable to Start PrEP Today?
Individuals at higher risk of HIV—such as those with multiple partners, inconsistent condom use, or partners with unknown HIV status—are among the groups who should consider starting PrEP now, as current approved options provide effective protection when taken correctly.
People who experience recurring risk situations or changes in sexual behavior may also benefit from professional consultation to assess whether PrEP is appropriate for them. Starting with established PrEP methods available today ensures immediate protection without waiting for future medication developments.
What Should You Do While Waiting for New PrEP Options?
While once-monthly oral PrEP is still under clinical investigation, the safest approach is to rely on prevention methods that are already proven, such as daily PrEP or consistent condom use. Choosing options supported by strong evidence ensures reliable protection against HIV.
Regular HIV testing is also recommended, especially for individuals with ongoing risk, along with consulting healthcare professionals to determine the most suitable prevention plan. Starting with the currently available methods provides immediate protection without waiting for future medication approvals.
PrEP in Thailand: What to Know in 2026
In Thailand, the currently available PrEP options remain the approved forms, such as daily PrEP, which are widely used in clinics and hospitals as standard care. Access to services has improved, with specialized sexual health clinics and screening programs available for consultation and ongoing monitoring.
Once-monthly oral PrEP is not yet available in Thailand, as it is still in the research phase internationally. Individuals seeking HIV prevention should rely on proven, approved methods and follow medical guidance to ensure their prevention plan aligns with Thailand’s current healthcare context.
Frequently Asked Questions About Once-Monthly Oral PrEP
A common question is when once-monthly oral PrEP will become available. At this stage, there is no confirmed timeline, as the medication must first complete clinical trials and undergo regulatory review. Drugs under investigation cannot replace currently approved PrEP methods.
Questions about safety and side effects also arise frequently. Long-term data is still being collected, and clear conclusions will only be possible after the completion of ongoing studies. Until then, individuals should rely on credible scientific sources and consult healthcare professionals for accurate, up-to-date information.
Summary: The Future of Once-Monthly Oral PrEP and What You Should Do Now
Once-monthly oral PrEP represents a promising future direction in HIV prevention, offering the potential for greater convenience and wider accessibility. While early findings are encouraging, the medication must complete full safety and effectiveness evaluations before it can be approved for clinical use.
While awaiting further research, individuals seeking HIV protection should continue using currently approved methods, such as daily PrEP, along with regular health check-ups and professional guidance. Choosing an evidence-based approach available today remains the most reliable way to reduce risk immediately.
Reference
- Aidsmap. “Once-Monthly Oral PrEP Moves into Late-Stage Trials.” Aidsmap, July 2025
- PrEPWatch. “MK-8527 Long-Acting Oral PrEP Candidate.” PrEPWatch, 2025
- Merck Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
- Clinicaltrials A Study of MK-8527 to Prevent HIV
If you want to book appointment or consult more.
You can booking from website or social media this bottom section
